Ainos Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Ainos.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Sep 30

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Aug 24

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Aug 15

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Ainos no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:AIMD - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	0	-16	-6	-6	N/A
6/30/2024	0	-15	-6	-6	N/A
3/31/2024	0	-15	-5	-5	N/A
12/31/2023	0	-14	-5	-5	N/A
9/30/2023	1	-10	-4	-4	N/A
6/30/2023	3	-15	-4	-4	N/A
3/31/2023	3	-14	-4	-3	N/A
12/31/2022	4	-14	-4	-3	N/A
9/30/2022	3	-13	-4	-3	N/A
6/30/2022	1	-7	-3	-3	N/A
3/31/2022	1	-5	-3	-2	N/A
12/31/2021	1	-4	-1	-1	N/A
9/30/2021	1	-3	-1	-1	N/A
6/30/2021	0	-2	0	0	N/A
3/31/2021	0	-2	-1	-1	N/A
12/31/2020	0	-1	-1	0	N/A
9/30/2020	0	-1	-1	-1	N/A
6/30/2020	0	-1	-1	-1	N/A
3/31/2020	0	-2	-1	-1	N/A
12/31/2019	0	-2	-1	-1	N/A
9/30/2019	0	-2	-1	-1	N/A
6/30/2019	0	-2	-1	-1	N/A
3/31/2019	0	-2	-1	-1	N/A
12/31/2018	0	-1	-1	-1	N/A
9/30/2018	0	-1	-1	-1	N/A
6/30/2018	0	-1	N/A	-1	N/A
3/31/2018	0	-1	N/A	0	N/A
12/31/2017	0	-1	N/A	0	N/A
9/30/2017	0	-1	N/A	0	N/A
6/30/2017	0	-1	N/A	0	N/A
3/31/2017	N/A	-1	N/A	-1	N/A
12/31/2016	N/A	-1	N/A	-1	N/A
9/30/2016	0	-1	N/A	-1	N/A
6/30/2016	0	-1	N/A	0	N/A
3/31/2016	N/A	-1	N/A	0	N/A
12/31/2015	N/A	-1	N/A	0	N/A
9/30/2015	N/A	3	N/A	0	N/A
6/30/2015	N/A	3	N/A	-1	N/A
3/31/2015	N/A	3	N/A	-1	N/A
12/31/2014	N/A	3	N/A	-1	N/A
9/30/2014	N/A	-1	N/A	0	N/A
6/30/2014	N/A	-1	N/A	-1	N/A
3/31/2014	N/A	-1	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de AIMD es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de AIMD crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de AIMD crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de AIMD crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de AIMD crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de AIMD se prevé que sea elevada dentro de 3 años.

Ainos Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Ainos, Inc. Announces Institutional Review Board Approval for Sjögren’S Syndrome Clinical Study

Third quarter 2024 earnings released: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023)

Ainos, Inc. Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for HIV-Oral Warts Clinical Trial

Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for Hiv-Oral Warts Clinical Trial, Highlighting Value of Fda-Designated Orphan Drug Veldona

Ainos Announces Plan to Initiate Taiwan Clinical Study for Veldona as Potential Treatment of Oral Warts in HIV-Positive Patients

Ainos, Inc. Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety

Ainos, Inc., Annual General Meeting, Sep 27, 2024

Second quarter 2024 earnings released: US$0.49 loss per share (vs US$0.58 loss in 2Q 2023)

Ainos, Inc Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug

Ainos Receives a Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market

First quarter 2024 earnings released: US$0.57 loss per share (vs US$0.63 loss in 1Q 2023)

New major risk - Shareholder dilution

We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt

Full year 2023 earnings released: US$3.36 loss per share (vs US$5.14 loss in FY 2022)

Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms

New minor risk - Shareholder dilution

Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement

Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell

Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary

Less than half of directors are independent

Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.20 loss in 2Q 2022)

Staff of Nasdaq Determines Ainos is Eligible for an Additional 180 Calendar Day Period, or Until January 2, 2024, to Regain Compliance with Its Minimum Bid Price Requirement

Ainos, Inc. Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20 Million Revenue Target

Ainos, Inc. Announces Chief Financial Officer Changes

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.22 loss in 1Q 2022)

Full year 2022 earnings released: US$1.03 loss per share (vs US$0.52 loss in FY 2021)

Ainos Receives Non-Compliance Notice From Nasdaq

Ainos, Inc Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals

Third quarter 2022 earnings released: US$0.51 loss per share (vs US$0.12 loss in 3Q 2021)

Less than half of directors are independent

Ainos, Inc. Pursues Licensing Partners to Accelerate Five Candidates of Its Low-Dose Oral Interferon Formulation Veldona to Phase 3 Trials and Commercialization

Ainos Announces Positive Results from Additional Preclinical Study of Its Low-Dose Oral Interferon Formulation Against New Variant Virus - Omicron

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Second quarter 2022 earnings released: US$0.014 loss per share (vs US$0.09 loss in 2Q 2021)

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Ainos, Inc. has completed a Composite Units Offering in the amount of $3.315 million.

Less than half of directors are independent

Ainos Announces Positive Results from Preclinical Studies of Its Low-Dose Oral Interferon Formulation Against Covid-19

Ainos, Inc. Announces Executive Changes

Ainos, Inc. announced delayed 10-Q filing

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento